Assistant Professor, Surgery, University of Iowa College of Medicine
General Surgery
Dr. James J. Mezhir, MD
|
|
Give Review
James Mezhir practices General Surgery. He went to University at Buffalo, School of Medicine and Biomedical Sciences. He has 3 awards "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Fellow". James J. Mezhir has written publications. He has 49 publications published with PubMed. The lastest publication is: 'Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.' James Mezhir accepts Medicare payments and is registered with Medicare.gov.
Publications
- Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.
- Sarcopenia is an independent predictor of complications following pancreatectomy for adenoCarcinoma.
- Minimally Invasive Pancreatectomy for Cancer: A Critical Review of the Current Literature.
- Morbidity and Mortality Following Elective Splenectomy for Benign and Malignant Hematologic Conditions: Analysis of the American College of Surgeons National Surgical ...
- Pancreatectomy Predicts Improved Survival for Pancreatic Adenocarcinoma: Results of an Instrumental Variable Analysis.
- Failure to rescue as a source of variation in hospital mortality after hepatic surgery (Br J Surg 2014; 101: 836-846).
- The critical role of peritoneal cytology in the staging of gastric Cancer: An evidence-based review.
- An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic Cancer patients.
- Complications and survival associated with operative procedures in patients with unresectable pancreatic head adenoCarcinoma.
- A matched case-control study of IBD-associated coloRectal cancer: IBD portends worse outcome.
- A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.
- RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.
- Intraperitoneal drainage after Pancreatic resection: a review of the evidence.
- A comprehensive assessment of transfusion in elective pancreatectomy: risk factors and complications.
- Changes in the management of benign liver tumours: an Analysis of 285 patients.
- Rational design of a secreted enzymatically inactive mutant of extracellular superoxide dismutase.
- Molecular characterization of desmoid Tumors: decryption of the enigma.
- PancreaticoBiliary surgery for the treatment of malignancy: spread the word.
- Management of complications following Pancreatic resection: An evidence-based approach.
- Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers.
- Optimizing pancreatectomy outcomes: Follow the evidence.
- Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal Neuroendocrine tumors from a single institution.
- Positive Peritoneal Cytology in Gastric Cancer.
- Treatment and outcome of patients with gastric remnant Cancer after resection for peptic ulcer disease.
- Prognostic markers and staging systems for patients with coloRectal liver metastases.
- The Desmoid Tumor: Still an Enigma.
- Pyogenic abscess after hepatic artery embolization: a rare but potentially lethal complication.
- Positive peritoneal cytology in patients with gastric Cancer: natural history and outcome of 291 patients.
- Current management of pyogenic Liver abscess: surgery is now second-line treatment.
- Neoadjuvant therapy of locally advanced gastric Cancer.
- Randomized clinical trials in gastric Cancer.
- A matched case-control study of preoperative Biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified.
- Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive Disease.
- Adrenocortical Carcinoma invading the inferior vena cava: case report and literature review.
- Handlebar injuries in children: should we raise the bar of suspicion?
- Establishment of a syngeneic model of hepatic coloRectal oligometastases.
- ReVOLT: radiation-enhanced viral oncolytic therapy.
- Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1.
- Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in Tumors treated with oncolytic viruses.
- Presence of distal intramural spread after preoperative combined-modality therapy for adenoCarcinoma of the rectum: what is now the appropriate distal resection margin?
- Progression of Barrett's metaplasia to adenoCarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
- Prolyl-4-Hydroxylase 3 (PHD3) Expression Is Downregulated during Epithelial-to-Mesenchymal Transition.
- Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life.
- Microangiopathic hemolytic anemia as the first manifestation of lung adenoCarcinoma.
- Chemo-inducible gene therapy.
- Ionizing radiation: a genetic switch for Cancer therapy.
- Successful palliation of hypercalcemia secondary to metastatic parathyroid Cancer: an unusual indication for hepatic resection.
- The umbilical mass: a rare neonatal anomaly.
Schools
U OF BUFFALO SUNY SCH OF MED amp BIOMEDICAL SCI
Procedures Preformed
- Colectomy
- Cystectomy
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Excision of Stomach Tumor
- View All
Conditions Treated
- Abdominal Pain
- Anal and Rectal Cancer
- Anal Fissure
- Atelectasis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow
Education
-
University of Chicago -
University at Buffalo, School of Medicine and Biomedical Sciences
Drug Facts
| NPI NUMBER | 1851551964 | |
| NPPES Provider LastName | MEZHIR | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 522421007 | |
| NPPES Provider State | IA | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851551964 |
| Last Name Of The Provider | MEZHIR |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Joel Shilyansky, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter R. Jochimsen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Siroos S. Shirazi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald P. Kealey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah F. Burger, MD |
|
|
Dr. Peter N. Nau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claudia L. Corwin, MD |
|
|
Dr. Kevin D. Helling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew J. Jepson, MD |
|
|
Dr. Nathan G. Miller, MD |